{"id":"hlx10","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HLX10 targets programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing the PD-L1/PD-1 interaction that normally suppresses T-cell activation. By blocking this immune checkpoint, the drug allows cytotoxic T lymphocytes to recognize and attack cancer cells more effectively. This mechanism is used across multiple solid tumors where PD-L1 expression is associated with immune evasion.","oneSentence":"HLX10 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:53.990Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Gastric cancer"},{"name":"Esophageal cancer"}]},"trialDetails":[{"nctId":"NCT07487519","phase":"PHASE2","title":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-25","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC))","enrollment":180},{"nctId":"NCT07457528","phase":"PHASE2","title":"Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-12","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT05731726","phase":"PHASE2","title":"Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2023-02-22","conditions":"pMMR, MSS, MSI-L","enrollment":50},{"nctId":"NCT06857279","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04-22","conditions":"Carcinoma of Head and/or Neck","enrollment":167},{"nctId":"NCT07113275","phase":"PHASE3","title":"A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-02-11","conditions":"Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy","enrollment":435},{"nctId":"NCT07269782","phase":"PHASE2","title":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-01-20","conditions":"Non Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT05954429","phase":"PHASE2","title":"A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-07-20","conditions":"Colorectal Cancer","enrollment":50},{"nctId":"NCT05353257","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-05-17","conditions":"Limited-Stage Small Cell Lung Cancer","enrollment":511},{"nctId":"NCT07318883","phase":"PHASE2, PHASE3","title":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-03","conditions":"Squamous NSCLC","enrollment":720},{"nctId":"NCT04063163","phase":"PHASE3","title":"A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2019-09-12","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":585},{"nctId":"NCT06115642","phase":"PHASE1","title":"A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2023-11-24","conditions":"Advanced/Metastatic Malignant Solid Tumors","enrollment":340},{"nctId":"NCT06368141","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-05-01","conditions":"Colon Cancer","enrollment":56},{"nctId":"NCT06812260","phase":"PHASE2","title":"A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-06-24","conditions":"SCLC, Extensive Stage","enrollment":26},{"nctId":"NCT07141771","phase":"PHASE1, PHASE2","title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-12-31","conditions":"SCLC, Extensive Stage","enrollment":100},{"nctId":"NCT05787613","phase":"PHASE2","title":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2023-07-10","conditions":"NSCLC Stage IV","enrollment":132},{"nctId":"NCT05831891","phase":"PHASE2","title":"Fruquintinib and SeRplulimab: Opening New Frontiers in Treating Non-clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-05-01","conditions":"Non-clear Renal Cell Carcinoma","enrollment":39},{"nctId":"NCT06349980","phase":"PHASE2","title":"A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2024-08-05","conditions":"Carcinoma, Hepatocellular","enrollment":117},{"nctId":"NCT04547166","phase":"PHASE2, PHASE3","title":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2021-03-10","conditions":"Metastatic Colorectal Cancer","enrollment":568},{"nctId":"NCT05584137","phase":"PHASE2","title":"Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC","status":"TERMINATED","sponsor":"Shanghai Henlius Biotech","startDate":"2023-06-15","conditions":"Colorectal Cancer Metastatic","enrollment":2},{"nctId":"NCT05765825","phase":"PHASE2","title":"Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2023-03-07","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":61},{"nctId":"NCT05513573","phase":"PHASE2","title":"Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-12-14","conditions":"Nasopharyngeal Carcinoma by AJCC V8 Stage","enrollment":75},{"nctId":"NCT06447454","phase":"","title":"Combining Chemoradiotherapy With Sintilimab in First-Line ICC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-07-01","conditions":"ICC","enrollment":19},{"nctId":"NCT05443646","phase":"PHASE2","title":"Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-09-23","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":55},{"nctId":"NCT06370065","phase":"PHASE2","title":"Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-27","conditions":"Advanced Hepatocellular Carcinoma","enrollment":35},{"nctId":"NCT05483530","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-12-14","conditions":"Advanced or Metastatic Solid Tumors","enrollment":20},{"nctId":"NCT06350162","phase":"PHASE2","title":"Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-10-18","conditions":"Extensive Stage Lung Small Cell Cancer","enrollment":100},{"nctId":"NCT06334757","phase":"PHASE2","title":"Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2023-05-08","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":46},{"nctId":"NCT06335147","phase":"NA","title":"PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2024-04-01","conditions":"Metastatic Colon Cancer","enrollment":23},{"nctId":"NCT05400265","phase":"PHASE1","title":"Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2022-07-26","conditions":"Adult Solid Tumor","enrollment":9},{"nctId":"NCT03952403","phase":"PHASE3","title":"A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2019-12-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":643},{"nctId":"NCT04033354","phase":"PHASE3","title":"A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2019-08-14","conditions":"Squamous Non Small Cell Lung Cancer","enrollment":537},{"nctId":"NCT04297995","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2020-07-29","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":131},{"nctId":"NCT05883670","phase":"","title":"Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2023-03-09","conditions":"Cervical Cancer","enrollment":118},{"nctId":"NCT03958890","phase":"PHASE3","title":"A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2019-06-19","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":489},{"nctId":"NCT05641493","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2023-02-28","conditions":"Non Small Cell Lung Cancer","enrollment":49},{"nctId":"NCT05769725","phase":"PHASE2","title":"A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-03-01","conditions":"Serplulimab,Gastric Cancer, Adjuvant Therapy","enrollment":70},{"nctId":"NCT03941574","phase":"PHASE2","title":"A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2019-07-15","conditions":"MSI-H Solid Malignant Tumor","enrollment":108},{"nctId":"NCT05221658","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-08-25","conditions":"ESCC or Esophageal Adenosquamous Carcinoma","enrollment":60},{"nctId":"NCT05501340","phase":"PHASE1, PHASE2","title":"PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2022-09-01","conditions":"Malignant Ascites","enrollment":40},{"nctId":"NCT05442996","phase":"PHASE1","title":"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2023-01-06","conditions":"Solid Tumor, Adult","enrollment":30},{"nctId":"NCT04139135","phase":"PHASE3","title":"A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2019-12-12","conditions":"Gastric Cancer","enrollment":642},{"nctId":"NCT04150575","phase":"PHASE2","title":"A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2020-03-10","conditions":"Cervical Cancer","enrollment":21},{"nctId":"NCT04976647","phase":"PHASE2","title":"A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-01-18","conditions":"Squamous Non-small-cell Lung Cancer","enrollment":156},{"nctId":"NCT04806945","phase":"PHASE3","title":"A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer","status":"WITHDRAWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-09-30","conditions":"Cervical Cancer","enrollment":""},{"nctId":"NCT04465734","phase":"PHASE3","title":"A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC","status":"WITHDRAWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-11-15","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":""},{"nctId":"NCT05354700","phase":"PHASE2","title":"A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2023-03-29","conditions":"Small-cell Lung Cancer","enrollment":20},{"nctId":"NCT05290220","phase":"PHASE2","title":"HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-08-01","conditions":"Advanced Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT05239650","phase":"PHASE2","title":"Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-07-15","conditions":"CRC","enrollment":50},{"nctId":"NCT05246982","phase":"PHASE2","title":"HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-03-23","conditions":"Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)","enrollment":40},{"nctId":"NCT05311189","phase":"PHASE2","title":"Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-04-15","conditions":"HER2-positive Gastric Cancer","enrollment":40},{"nctId":"NCT03973112","phase":"PHASE2","title":"A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2019-09-24","conditions":"Hepatocellular Carcinoma","enrollment":123},{"nctId":"NCT04947826","phase":"PHASE2","title":"Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08","conditions":"Hepatocellular Carcinoma With Major Portal Vein Thrombosis","enrollment":100},{"nctId":"NCT04133259","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Henlix, Inc","startDate":"2019-12-31","conditions":"Hepatitis B, Chronic","enrollment":44},{"nctId":"NCT03468751","phase":"PHASE1","title":"Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Henlix, Inc","startDate":"2018-02-14","conditions":"Solid Tumor","enrollment":30},{"nctId":"NCT04301739","phase":"PHASE3","title":"to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2020-04-17","conditions":"Triple Negative Breast Cancer","enrollment":522},{"nctId":"NCT03757936","phase":"PHASE1","title":"A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2018-11-27","conditions":"Solid Tumor","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"EATING DISORDER"},{"count":1,"reaction":"LYMPHOCYTE COUNT DECREASED"},{"count":1,"reaction":"NEUTROPHIL COUNT DECREASED"},{"count":1,"reaction":"WHITE BLOOD CELL COUNT DECREASED"}],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant humanized anti-PD-1 monoclonal antibody injection","Serplulimab","Anti-PD-1 Humanized Monoclonal Antibody","SERPLULIMAB","anti-PD-1 monoclonal antibody"],"phase":"phase_3","status":"active","brandName":"HLX10","genericName":"HLX10","companyName":"Shanghai Henlius Biotech","companyId":"shanghai-henlius-biotech","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HLX10 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Gastric cancer, Esophageal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":10,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}